SPY326.97-3.68 -1.11%
DIA271.44-5.08 -1.84%
IXIC10,778.80-14.48 -0.13%

Takeda Pharmaceutical and Ovid Therapeutics Announces Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut Syndrome

Benzinga · 08/25/2020 11:07